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Abstract The aimofthis studywas (1) to evaluatethe effectsof long-termoxygentreatment (LTOT) inelderlypatients
with severe exacerbations of chronic obstructive pulmonary disease (COPD) and hypoxaemia, (2) to study the health-
related quality of life (QOL) during hospital stay and at follow-up, (3) to study the safety of an oxygen withdrawal test
performed a fewdays after admissionto hospital and the possibility to predictthe future need for LTOT fromthattest.
Patients470 yearswith COPD-exacerbationswith hypoxaemiawere included after 527 days treatment in hospital.
Inclusionwas based on results of a standardised oxygenwithdrawal test. After1, 3, 6 and12 months a new oxygen with-
drawal test was performed.Health-related QOL was evaluatedwith SF-36 and the St George’s Respiratory Question-
naire atinclusion andafter 3,6 and12months.Forty-sevenpatientswere screened forparticipation and 29 patients,mean
age 79 years, participated in the study.Onlyone patientcould nottolerate the oxygenwithdrawal test.Eighteenpatients
survivedtothe follow-up after12months,8/19women and 2/10mendied.After1month LTOTwasneeded (PaO2without
oxygenwasr7.5 kPa) inonly 6/20 patients.The effectof LTOT couldthereforenotbe studied.Mostcomponentsof SF-36
wereverylowat inclusion, buttended to increase after 3 months andwere among the survivingpatients after12 months
similar tothatof healthypeopleofthe sameage forpsychicwellbeingandfunctioning.Especially, the symptomscoreofthe
SGRQimproved after 3 months.
In conclusion, the future need for LTOT cannot be judged after a few days treatment in hospital due to exacerbations
with hypoxaemia in elderly patients with COPD. A standardised oxygenwithdrawal test can be safely done.Health-re-
lated QOL is low in patients during the stay in hospital, but improves after returning home. r 2002 Elsevier Science Ltd.
Allrights reserved.
Available online athttp://www.sciencedirect.com
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It is well established that long-term oxygen therapy
(LTOT) increases survival in patientswith chronic hypox-
aemia and chronic obstructive pulmonary disease
(COPD) (1). Studies of LTOT in COPD-patients did not,
however, include elderly people. Patients included were
either younger than 70 years (2) or their mean age was
65.5 years (3).Themean age of patients in Sweden start-
ing LTOT increases year by year according to the Swed-
ish Oxygen Registry (4). The mean age of patients
receiving LTOTwhen this study was started in1997 wasReceived 8 April 2002, accepted in revised form 8 April 2002.
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Lund, Sweden, E-mail: kerstin.b.pehrsson@skane.se72.0 (SD 9.5) years. No studies have been performed on
the e¡ects of LTOT in patients over 70 years.
Furthermore, due to the lackof hospitalbeds,patients
are today commonly starting LTOTafter only a few days
stay in hospital when their respiratory performance still
is unstable. Decisions on LTOT prescriptions are based
on oxygen withdrawal tests, but we lack good evidence
concerning the safety of such tests and titration of oxy-
gen after discharge (5). The recommendations concern-
ing LTOT state that the need for oxygen should be
judged after the patients have been treated optimally
and been in a stable state for 3 weeks (6).
The original purpose of the presentwork including el-
derly COPD patients hospitalised due to a severe hypox-
aemic exacerbationwas to study : (1). the e¡ect of LTOT
on survival and time to readmission to hospital; (2).The
possibility to predict the future need of LTOT after a
LONG-TERMOXYGENTHERAPY 945short stay in hospital by performing an oxygen withdra-
wal test; (3).The health-related quality of life (QOL) dur-
ing the stay in hospital and at follow up.
It was, however, found that after 1 month therapy
LTOTwas no longer indicated in a majority of the pa-
tients.The primary objective of the study could, there-
fore, not be achieved and the study was interrupted.
Thus, the focus of the present paper is on the second
and third objectives of the study.
METHODS
Study design
Patients admitted to the Lung Clinic Sahlgrenska Univer-
sity Hospital or the Geriatric Clinic Dstra University
Hospital Gothenburg due to respiratory insu⁄ciency
caused by COPD and aged470 years were eligible for
the study andwere consecutively asked for participation.
Smoking history was assessed and patients who had
stopped smokingpreviouslyor stoppedduring the hospi-
tal stay were asked to participate. An oxygenwithdrawal
test was performed and patients with PaO2 r7.5kPa
were randomised to LTOT or not LTOT. Patients with
PaO2 o6.5kPa were given LTOT. The study nurse per-
formed a visit to the homes of patients recieving LTOT
after1month. All patients came to the out-patients clinic
after 3, 6 and 12 months. Blood-gas tests without and
with oxygenwere performed before leaving hospital and
after1, 3, 6 and12months.QOLquestionnaireswere¢lled
in before leaving hospital and after 3, 6, and12 months.
Patients and oxygenwithdrawal test
Patientso70 years oldwith a clinical diagnosis of COPD
and with hypoxaemia (PaO2 r7.5 kPa) after an oxygen
withdrawal test were included. A clinical diagnosis of
COPDwas based on a long smoking history, progressive
dyspnoea, X-ray changes andblood-gas values.However,
one patient was a life-long non-smoker.He had homozy-
gotic alfa-1 antitrypsin de¢ciency. It was possible to per-
form spirometry in 20 patients. Patients currently
smoking or patients with linguistic problems, dementia
or other severe diseases as judged by the investigator
were not included.
An oxygen withdrawal test was performed after 5^7
days hospital treatment, if oxygen saturationwas485%
after 5pm.Oxygen was omitted until the day after. Ar-
terial blood-gas sampling was done at 11 a.m. in supine
position without oxygen therapy after 20min rest. Pa-
tientswith 6.5rPaO2r7.5kPawere asked in a standar-
dised way if they felt any di¡erence with or without
oxygen treatment. If they did not feel a di¡erence they
were randomised to LTOTor not LTOT. If they felt dis-
comfortwithout oxygen they wereprescribed LTOT. Pa-
tients with PaO2o6.5 kPa were also prescribed LTOT.Before each follow-up visit oxygen was omitted for 1^
12h in all patients.
Physiologicalmeasurements
Arterial blood gas measurements, including oxygen ten-
sion (PaO2), carbon dioxide tension (PaCO2) and stan-
dard bicarbonate were determined (Radiometer ABL 2)
in samples of blood obtained from all patients in the su-
pine position. Transcutaneous oxygen saturation was
measured by a NONIN oxymeter.
Routine spirometry was performed less than 1 year
before the start of the study. Vital capacity (VC) and
forced expiratory volume (FEV1) were measured using a
Sensormedics spirometer, 15min after the inhalation of
1mg terbutaline.Normal values were predicted accord-
ing to Berglund (7).
Body mass index (BMI) was calculated from height
measured to the nearest 0.5 cm and weight measured
on a Lindelltronic Scale to the nearest 0.1kg.
Health-relatedQOL questionnaires
Generic.The Swedish SF-36 is awell-validated translation
(8) from the International SF-36. It is a measure of the
patient‘s overall health status (9). It comprises 36 items
groupedinto eightcategories.These areused to describe
wide aspects of health including physical functioning,
mental well-being and social functioning.The results are
given as per cent, where100 is the highest possible score
in each category.High scores indicate better functioning.
A clinically important di¡erence is considered to be
5^10% (9).
Disease speci¢c.Weused avalidated Swedishversion of
the St George’s Respiratory Questionnaire (SGRQ)
(10,11). It has 76 items divided into three sections: symp-
toms, activity and impacts. Every item has a predeter-
mined weight quantifying the severity of problems or
limitations. The scores range from 0 to 100% of possible
distress. High scores indicate dysfunction and a cut-o¡
point45% was applied for clinical signi¢cance. A total
scorewas also calculated according to the questionnaire
instructions.
Statistics
Distribution of variables are given as means, standard
deviation (SD) and for QOL measures 95% con¢dence
interval (CI) are presented. Fisher’s non-parametric
permutation test was used for comparison between
groups (12). Signi¢cance levels were conducted at
the 5% level.
Ethics
The study was approved by the ethics committe of the
Sahlgrenska University Hospital.
TABLE 1. Age, sex, FEV1 in per cent predicted, BMI, ar-
terial PaO2 in air and SGRQ total score at inclusion of the
18 patients surviving 12 months follow-up and the 10 not
surviving the follow-up.
Survived
12 months
(n= 18)
Died during
12 months
followup
(n= 10)
Age 77.6 (4.5) 79.9 (4.4)
Sex, % men 80 20
FEV1% predicted 30% (n= 16) 29% (n= 4)
BMI 21.3 (4.3) 21.4 (5.5)
PaO2 6.4 (1.0) 6.3 (0.7)
SGRQ total 54.3 (46.2;61.8) 61.5 (49.5;73.5)
Values aremean (SD) and for SGRQmean (95% CI).
TABLE 2. Comparison of age, sex, FEV1, PaO2, BMI and
SGRQ at inclusion for the six patients who were hypoxic
(pO2r7.5 kPa) without oxygen and the14 patients who
were not hypoxic after1month in the oxygenwithdrawal
test
Oxygen demand
after1month
(n= 6)
Notoxygen
demand after
1month (n= 14)
Age 80.0 77.9
Sex (men/women) 1/5 7/7
FEV1percentpredicted 33% ( (n= 5) 32% (n= 10)
PaO2, kPa 5.7 (4.1^6.4) 6.4 (5.4^7.5)
BMI 20.6 (14.9^28.6) 21.8 (16.0^29.3)
SGRQ total 43.6 (29.0;54.7) 60.1 (7.3;84.7)
Values aremean (range) and for SGRQmean (95% CI).
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Forty-seven patients were screened for participation.
Seven patients did not want to participate due to fear of
being allotted to oxygen treatment. Two had linguistic
problems. Five were current smokers and three had de-
mentia. Thirty patients (10 men) were thus included in
this study. One patient, however, deteriorated immedi-
ately after inclusion and could not be followed further.
Twenty-nine patients started the study and are pre-
sented (Fig. 1). The initial oxygen withdrawal test could
be carried out in all but one patientwho did not tolerate
the withdrawal. Discomfort during oxygen withdrawal
was reported by no other patient. Eleven patients were
randomised (group1a or1b) to eitheroxygen (n=5) or no
oxygen (n=6). Eighteen patients were treated with oxy-
gen due to PaO2o6.5 kPa at the ¢rst oxygenwithdrawal
test (group 2).
The mean (SD) FEV1 as per cent predicted was 30%
(11%) (range16^57%), (n=20). At the inclusion the mean
(SD) age for men was 79 years (4.2) and for women 78
years (4.6). The mean (SD) PaO2 without oxygen was
6.6 kPa (0.8) for men and 6.2kPa (0.9) for women. The
mean (SD) PaCO2 for men was 6.2 kPa (1.0) and for wo-
men 6.9kPa (0.9). The mean (SD) BMI for men was 21.5
(4.0) and for women 22.1 (6.2).
Eighteen patients survived until the follow-up after
12 months (Fig 1). Ten patients died during the 12
months follow-up. Six died due to respiratory failure.
Eight of the 23 patients with LTOT died and 2/6 without
LTOT. One patient, not treated with oxygen, dropped
out after 1 month due to progressive amyotrophic
lateral sclerosis.
At inclusion, PaO2 and BMI did not di¡er between pa-
tients who survived and those who did not (Table 1).
Therewas a trend thatmorewomen thanmen died dur-
ing the follow-up year (8/19 women compared to 2/10
men). SGRQ total score was higher (ns) at inclusion
among the patients who died during the follow-up year.
The oxygen tension without oxygen treatment at the
home visit after one month was r7.5kPa in only 6/20
patients (Table 2). After three months PaO2 wasFIG. 1. Total number of patients at inclusion, after1, 3, 6 and12
months.The patientswith oxygentreatmentgiven as blackbars.r7,5kPa in 5/17 patients and after six months PaO2
was r7.5kPa in 8/14 patients. Trends, but no statistical
di¡erences, were found that higher age, female sex, low-
er PaO2 and lower BMI at inclusion correlated with the
need for oxygen after1month.
Health-relatedQOL
The physical component of SF-36 as well as scores for
role emotional, general health and vitality were low in
the patient group at inclusion (Table 3). High scores for
symptoms, activity and impact was recorded in the
SGRQ. There was a tendency towards better physical
health-related QOL recorded by the SF-36 after 3
months (Table 4 and Fig. 2). The largest improvement
was, however, seen for role emotional. Also social func-
tioning and general health seemed to improve after 3
months. In the SGRQ, symptoms decreased considerably
TABLE 3. SF-36 and SGRQin allpatients (n= 27 or 28) at
inclusion
At inclusion
Physical functioning (PF) 20.3 (12.0;28.5)
(n= 23)
Role physical (RP) 12.0 (2.8;21.3)
Bodilypain (BP) 59.2 (44.0;74.5)
Generalhealth (GH) 33.3 (25.7;40.9)
Vitality (VT) 29.6 (21.3;37.9)
(n= 26)
Social functioning (SF) 47.2 (33.2;61.2)
Role emotional (RE) 28.4 (11.0;45.8)
Mentalhealth (MH) 55.0 (44.3;65.8)
(n= 26)
Symptom 58.7 (50.1;67.4)
Activity 67.5 (59.1;75.8)
Impact 50.2 (43.6;56.8)
Total SGRQ 56.8 (50.5;63.2)
Values aremean (95% CI).
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for 12 months improvements noted after 3 months was
stable up to12 months (Fig. 2,Table 5).
The groups of patients randomised to LTOT or
not LTOT were too small for statistical calculations.
On the whole, improvements noted for SF-36
seemed to be larger in the non-oxygen-treated
group. For SGRQ, the picture was more heterogeneous
(Table 4).TABLE 4. SF-36 and SGRQatinclusiontime andthe di¡erence fr
mised to LTOT (n= 5) ornot LTOT (n= 6).
Patientswith
LTOT,
at inclusion
Patients
with LTOT,
di¡erence
frominclusion
3 months
PF 29 10
RP 15 16
BP 69 6
GH 33 8
VT 27 18
SF 48 15
RE 40 27
MH 60 21
Symptom 58 23
Activity 74 4
Impact 45 10
SGRQ total 56 14
Values aremean.DISCUSSION
The results of the present study are in line with those
reported in younger patients with COPD as the need
for LTOT could not be decided after a short stay in hos-
pital due to a hypoaxaemic exacerbation (13). In this
study, only 30% of the patients 1 month after discharge
had hypoxaemia after oxygen withdrawal.Compared to
the NOTT-study in which only 20% no longer needed
LTOT 3 weeks after discharge; this is a very low propor-
tion which might re£ect that the decision concerning
LTOTwas taken much earlier in the present study than
in the NOTT-study. Although high age; female gender
andlowQOLwere slightlyover representedin thegroup
that needed oxygen after 1 month, the correlation was
not statistically signi¢cant.Thus, there is a need for a re-
evaluation of the need for LTOT by performing a with-
drawal test 1month after initiating LTOT if patients are
in an unstable phase when home oxygen therapy is
started.This study indicates that after a short period of
treatment, an oxygenwithdrawal test canbe done safely
andwithout discomfort formost patients if the transcu-
taneous oxygen saturation before the test is485%.
Concerning risk factors in the present study old age
and poor self-reported QOL seem to indicate poor 1
year survival in COPD patients after admission due to
an exacerbation.This is in line with other studies (14,15).
Also female gender seamed to be a risk factor for death
within 1 year in the present study.We have not identi-
¢ed studies in which gender as a risk factor for poor
prognosis after hospital stay due to a serious exacerba-
tion of COPD have been analysed. However, there areominclusionto after 3monthsin11patientswhowererando-
to
Patientswithout
LTOT,
at inclusion
Patients
without
LTOT,
di¡erence from
inclusionto
3 months
18 16
13 18
45 24
29 19
11 32
59 4
33 25
40 32
57 7
75 13
46 7
57 9
020
40
60
80
100
PF RP BP GH VT SF RE MH
Inclusion
3 months
12 months
SF-36
FIG. 2. Meanvaluesofthe eight subscales ofthe SF 36 (PF,phy-
sical functioning; RP, role physical; BP, bodily pain; GH, general
health; VT, vitality; SF, social functioning, RE, Role emotional;
MH, mental health) in the18 surviving patients at inclusion, after
3 and12 months
TABLE 5. SGRQinthe18 survivingpatients during the12
months follow-up
Inclusion
time
After
3 months
After
12 months
Symptoms 60 (48;72) 42 (31;54) 46 (33;60)
Activity 66 (56;76) 65 (53;76) 61 (48;73)
Impact 46 (37;54) 44 (33;55) 45 (36;53)
Total 54 (46;62) 49 (38;60) 49 (40;57)
Values aremean (95% CI).
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than in men.The need for hospital care is more (16).The
prognosis especially in steroid-treatedwomenwith LTOT
is worse than inmen (17).
Health-relatedQOLof our patients still in hospital re-
garding the generic questionnaire SF-36 was low in com-
parison with other populations with chronic diseases. In
a study in which the SF-36 questionnaire was evaluated
several patient groups were included (18). Compared to
those groups our patients in some aspects (e.g. role lim-
itation because of physical health problems) reported
extremely low values. Compared to a group of patients
hospitalised due to AIDS, our patients reported the
same low level of general health and vitality (18). Emo-
tional role, mental health and social functioning were at
the same low level or lower than that reported by the
group of AIDS-patients and a group of patients with ¢-
bromyalgia.
Our patients, still in hospital showed low SF-36 values
compared to other patients with COPD. Out-patients
with COPD and a mean age of 52 years of which 79%
were male had considerably higher estimates for all do-
mains of the SF-36 (19). A group of outpatients with
COPD and signi¢cant co-morbidity, however, had similar
scores as the present group of hospitalised COPD pa-
tients for most domaines of the SF-36 except for roleemotional that was more severely a¡ected in our group
of patients (20).
According to the disease-speci¢c questionnaire SGRQ
the symptoms, activities and impact domains of the dis-
easewere similar in our group of patients and in a group
of younger outpatients with COPD (19). Compared to
the COPD group with co-morbidity, SGRQ ratings in
our groupwas lower for symptoms and activity and simi-
lar for impact. Thus, in our group of hospitalised pa-
tients, the e¡ects of the disease on daily living as
re£ected in the SF-36 seems to be worse than themore
disease-speci¢c e¡ects studied bymeans of the SGRQ.
During the year of observation values for SF-36 im-
proved. The greatest change compared to base line oc-
curred already during the ¢rstmonth of stay at home. It
is possible that the low values reported during the stay
in hospital partly constitute an e¡ectof the exacerbation
and partly of the hospitalisation. The improving ¢gures
after returning home is probably due to a change in both
medical status and environment.
The improvement seen in the disease speci¢c ques-
tionnaire SGRQ thatwasmostevident for the symptoms
domain indicates an improvement of themedical status.
We found no evidence that LTOT improved the QOL.
This is not surprising as in only a small group of patients
there was a continued need for LTOT.On the contrary,
there is a tendency that LTOT decreased QOL (Table 4).
Oxygen therapy may be uncomfortable and restrict ac-
tivity for some patients. It is also interesting that some
patients denied participation in the study due to fear of
being allocated to LTOT.Themedical usefulness of LTOT
in elderly patients with COPD therefore need to be bet-
ter documented.
The values for SF-36 after 12 months follow up in the
survivor group were surprisingly high. They showed
equal or even better values than values reported by
younger COPD patients recruited for a rehabilitation
study (21).Thismightbe surprising, but low self-reported
QOL couldbe related to patientsŁ decision to takepart in
a rehabilitation programme and high self-reported QOL
seems, as discussed above, to be related to survival in
COPD patients. The patients surviving for 1 year in our
study represented a highly selected group as approxi-
mately 35% of the included patients had died during the
study year.Our surviving patients showedvalues for psy-
chic well-being and functioning which were equal to a
normal group of Swedes of the same age (8).
We conclude that the future need for LTOT cannot be
judged after a few days of treatment in hospital due to
exacerbation with hypoxaemia in elderly patients with
COPD. An oxygen withdrawal test can be safely done
after 5^7 days treatment if the transcutaneous oxygen
saturation is 485%. An oxygen withdrawal test must
be performed after 1 month of oxygen treatment to
make a decision on continued LTOT. Health-related
QOL is low in patients during the exacerbation and stay
LONG-TERMOXYGENTHERAPY 949in hospital, but improves after returning home and in
survivors the important aspects are similar to that
of healthy people of the same age. We also conclude
that this study emphasises the need for further
studies of LTOT in larger groups of elderly patients
with COPD.
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